Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. Why did this happen? For more information you can review our Terms of Service and Cookie Policy. Eliquis, which made up about 21% of the companys total sales in the latest reported quarter, faces U.S. market exclusivity loss after 2026. Eliquis, which made up about 21% of the companys total sales in the latest reported quarter, faces U.S. market exclusivity loss after 2026.
This drug range for Eliquis is 2026.74, which represents 40% of the total value for their professional portfolio.
( z0 range :ARG0-of ( z1 represent :ARG1 ( z2 percentage-entity :quant-of ( z3 thing :ARG2-of ( z4 value :ARG1 ( z5 portfolio :mod ( z6 professional ) :poss ( z7 they ) ) ) :ARG2-of ( z8 total ) ) :value 40 ) ) :ARG1 ( z9 product :name ( z10 name :op "Eliquis" ) ) :ARG3 ( z11 drug ) :ARG4 2026.74 :mod ( z12 this ) )
(z0 / range-01
    :ARG0-of (z1 / represent-01
                 :ARG1 (z2 / percentage-entity
                           :quant-of (z3 / thing
                                         :ARG2-of (z4 / value-01
                                                      :ARG1 (z5 / portfolio
                                                                :mod (z6 / professional)
                                                                :poss (z7 / they)))
                                         :ARG2-of (z8 / total-01))
                           :value 40))
    :ARG1 (z9 / product
              :name (z10 / name
                         :op1 "Eliquis"))
    :ARG3 (z11 / drug)
    :ARG4 2026.74
    :mod (z12 / this))
This drug range for Eliquis is 2026.74 , which represents 40 % of the total value for their professional portfolio .
z0 :ARG3 z11
z0 :mod z12
z0 :ARG1 z9
z9 :name z10
z10 :op1 2
z0 :ARG4 0
z0 :ARG0-of z1
z2 :value 1
z1 :ARG1 z2
z3 :ARG2-of z4
z3 :ARG2-of z8
z2 :quant-of z3
z5 :mod z6
z5 :poss z7
z4 :ARG1 z5